KR101281827B1 - Compound containing piperine for promoting absorption of Panax ginseng saponin - Google Patents

Abstract

The present invention relates to a composition for promoting the absorption of saponin in the body containing piperine as an active ingredient and a composition for promoting the absorption of ginseng saponin for the combined administration of piperine and ginseng saponin containing piperine and ginseng saponin as an active ingredient, More specifically, the present invention relates to a composition capable of improving the absorption rate of saponin by promoting metabolism of saponin introduced into the body by the black pepper-derived piperine and enhancing the conversion into compound K, which is an absorption form in the body. The composition of the present invention can maximize the antioxidant effect of saponin in the human body due to the action of pipelin.

Description

Compound containing piperine for promoting absorption of Panax ginseng saponin}

The present invention relates to a composition for promoting the absorption of saponin in the body containing piperine as an active ingredient and a composition for promoting the absorption of ginseng saponin for the combined administration of piperine and ginseng saponin containing piperine and ginseng saponin as an active ingredient, More specifically, the present invention relates to a composition capable of improving the absorption rate of saponin by promoting metabolism of saponin introduced into the body by the black pepper-derived piperine and enhancing the conversion into compound K, which is an absorption form in the body.

Korean ginseng (Panax ginseng CA Meyer) is a perennial herb belonging to the genus Panax of Araliaceae , and its root is called ginseng radix in medicinal herbs.

The main pharmacological effects of ginseng are saponin, which is purified by Shibata and Tanaka's research team. PPD (C ₃₀ H ₅₀ O ₃ ) and PPT (C ₃₀ H ₅₂ O ₄ ) , And it has a molecular weight of about 800 to 1200. The separation of ginsenosides from Korean ginseng was carried out by Shibata's research team using 13 TLC methods.Olenan-based saponin ginsenosides -Ro and ginsenosides -Ra, -Rb1, -Rb2,- Rc, -Rd, -Re, -Rf, -Rg1, -Rg2, -Rg3, -Rh and the like. Since 1968, the first chemical structure of ginsenoside-Rg1 isolated by TLC method has been reported, so far, about 34 types of ginsenosides have been identified. The first scientific study of ginseng components was reported in 1854 by Garriques of the United States, separating amorphous glycosides from American ginseng (Panax quinquefolium L.) and designating it as panaquiron. In 1957, Soviet pharmacologist Brekhman reported saponin glycosides as an active ingredient that indicates the pharmacological efficacy of ginseng. Saponin is a chemical glycoside, a kind of compound, and its origin comes from sapo (soap) because of its foaming properties. Saponins are glycosides that are chemically colored in red by Libermann-Buchard reaction and have sugars bound to sapogenin (aglycone). Saponins are classified into two types, triterpenoid-based saponins and steroid-based saponins, depending on the skeleton structure of aglycone, and saponins of Korean ginseng are triterpenoid-based salineins, which exist only in plants of the genus Panax. Its unique saponin has been found to be very mild, not toxic by excessive projections, and very little hemolytic action. The saponins of Korean ginseng are divided into two groups: protoparnaxadiol-based saponins (PPD) in two, and protopanaxatriol-based saponins (PPT) in three according to the number of -OH attached to the non-sugar portion. Sugars such as glucose, rhamnose, xylose, and arabinose are ether-bonded to -OH at the R1, R2, and R3 positions of the protopanaxatriol to form ginseng saponin. Saponins, the main components of ginseng (red ginseng), are mainly ginsenosides -Rb1, -Rb2, -Rc, and -Rd. These are glycosides, which combine 3 to 4 sugars and have high molecular weight. It is not easily absorbed into the body in human digestion, and sugars bound to the basic aglycone of saponins are separated by certain microorganisms in the intestine, which are then absorbed into the body.

   <Protopanaxadiol>

  <Protopanaxatriol>

<Oleanolic acid>

The pharmacological action of ginseng saponin has been revealed through pharmacological experiments, and various kinds of ginsenosides, saponins in ginseng, have excellent pharmacological activity in circulatory and central nervous system, antioxidant, anticancer, antidiabetic and immune function control. It is reported to have. Despite the excellent pharmacological efficacy of ginseng, it has been reported that the efficacy of ginseng, which differs from person to person, is due to the difference in the enzymatic activity of intestinal microorganisms in the human intestine. The process by which ginsenoside receives intestinal bacteria metabolism is as follows. First, propanaxadiol compounds ginsenosides Rb1, Rb2, Rc, etc. are metabolized to compound K via ginsenoside F2. Such metabolic reactions are catalyzed by bacteria of the genus Bacteroides , genus Fusobacterium , genus Provetella , and the like. In addition, ginsenosides Re, Rg1, and Rf, which are protopanaxatriol-based compounds, are metabolized to ginsenosides Rh1 or compound K by the strains and are absorbed into the body.

According to data reported by the Korean Society of Food Science and Nutrition, 37% of Koreans have no enzymes capable of degrading saponin in the body, or some of the enzymes are missing. Saponin was not able to decompose properly. The remaining 63% had enzymes capable of degrading saponin, but there were individual differences in the amounts of enzymes. Despite the excellent pharmacological efficacy of ginseng, the pharmacological effects of ginseng have not been fully exerted in the human body due to individual differences in absorption rate of saponin. Therefore, it is required to develop a method for increasing the absorption rate of saponin in the human body.

Therefore, the present inventors, while studying a method for increasing the absorption rate of ginseng saponin in the body, found that pipelin extracted from black pepper increases the absorption rate of ginseng saponin in the body, the present invention relates to a composition for increasing the absorption of ginseng saponin in the body Completed.

Accordingly, an object of the present invention is to provide a composition for increasing the absorption of ginseng saponin in the body using piperine extracted from black pepper having the effect of increasing the absorption rate of ginseng saponin in the body.

In order to achieve the object of the present invention, the present invention provides a composition for promoting absorption in ginseng saponin body containing piperine as an active ingredient.

In order to achieve another object of the present invention, the present invention provides a composition for promoting absorption of ginseng saponin in the body for the combined administration of piperine and ginseng saponin containing piperine and ginseng saponin as active ingredients.

Hereinafter, the present invention will be described in detail.

The present invention relates to a composition for promoting absorption in ginseng saponin body containing piperine as an active ingredient.

Piperin is represented by the following formula (2), and in one embodiment of the present invention was used pipelin extracted using black pepper fruit, which obtained the GRAS certification of the food additive US FDA was verified the raw material safety.

Piperine has been shown to enhance the intestinal absorption of several nutrients ( planta medica (1998) 64: 353-356, J. Nutr. Biochem (2000) 11: 109-113, Nutrition Research (1999) 19: 381-388). Piperine is induced by heat generation by piperine, which increases the blood supply to the gastrointestinal tract, increases enzyme levels such as gamma glutamyl transpeptidase, which is involved in enterocyte nutrient transport, promotes intracellular catabolism and increases total metabolism. It is known that the thyroid hormone levels involved in the development of heat increase. Recent research on metabolites of saponins has shown that the effects of ginseng saponins are not the saponins themselves but the intestinal bacteria metabolites. ( Chem Pharm Bull 38 (10) 2859-2861, Bio.Pharm Bull 25 (6) 743-747).

Compound K is a saponin of Protopanaxadiol family represented by the following formula (3). Compound K is a form that does not exist in ginseng itself. As a metabolism of intestinal bacteria, all of the sugar is removed from carbon 3, and only alcohol remains. Because all sugars do not fall and only one is left at carbon 20, it is made well by intestinal bacteria after ingestion, but it is not easily made in the external environment other than the intestine. Compound K is known to be known for its anti-inflammatory properties (Biol Pharm Bull. 2005 28: 652-6.), Hepatoprotective activity against toxic substances ( Liver Int. 2005 25: 1069-73.), Skin protection ( J Pharmacol Sci . 2005 99: 83-8.), Prevention of neurodegenerative diseases ( Neuropsychopharmacology. 2004 29: 860-8.), Inhibition of tumor growth ( Int J Cancer. 2006 118: 490-7.), Antioxidant activity (Ar Pharm Res 2004 27: 0.1136 to 40) and the like.

Piperin of the present invention promotes the metabolic action of saponin by heat generation and increases the conversion rate to compound K, which is a metabolite of saponin. Therefore, as a result, the composition of the present invention has a function of promoting the absorption of ginseng saponin in the body.

The present invention relates to a composition for promoting absorption of ginseng saponin in the body for the combined administration of piperine and ginseng saponin containing piperine and ginseng saponin as active ingredients.

As discussed above, piperine has the effect of promoting the metabolism of ginseng saponin in the body to be converted to Compound K so that ginseng saponin can be effectively absorbed into the body. Therefore, when co-administration of piperine and ginseng saponin is combined, the absorption rate of ginseng saponin in the body is enhanced, and can effectively exhibit pharmacological activity.

In one embodiment of the present invention, in order to determine whether the conversion rate of the piperine to compound K according to the promotion of saponin in vivo metabolism, ginseng saponin in combination with piperine, ginsenosides alone and the gene contained in the blood An experiment was conducted to determine the content of cenosides and compound K. As a result, when the combined administration of piperine and ginseng saponin, the content of ginsenosides Rb1, Rb2 and Rc in the blood was the largest increase after 1 hour, and it was confirmed that there is a sharp decrease thereafter. On the other hand, the saponin alone group showed the highest content of ginsenosides Rb1, Rb2 and Rc in the blood at 3 hours after administration, and the content was significantly lower than that in the case of co-administration with piperine. there was. These results show that piperine enhances the uptake of ginsenosides Rb1, Rb2 and Rc in the body.

In addition, in another embodiment of the present invention, in order to confirm the metabolic promoting effect of ginsenosides Rb1, Rb2 and Rc, the blood content of Compound K was measured. In the case of Compound K, the blood content increased significantly from 2 hours after the pipeline combination administration, and gradually decreased after 3 hours. However, in the saponin-only group, no compound K peak appeared until 5 hours after administration. These results indicate that ginsenosides are converted to Compound K, which is a form of body absorption, after 2 hours of ginseng saponin in combination with piperine. To show.

From the above results, the saponin absorption promoting composition comprising piperine of the present invention as an active ingredient, when administered in combination with ginseng saponin, promotes the conversion to compound K, which is an absorption form in the body, and enhances the absorption rate of saponin in the body. It can be seen that.

In addition, the pipelin may be extracted from black pepper, piper nigrum, long pepper, piper longum, cube, piper cubeba, or dill (Anethum graveolens). And preferably black pepper (Piper nigrum). In one embodiment of the present invention was used pipelin derived from black pepper.

In addition, the ginseng saponin is not limited thereto, but ginsenoside-Ro, ginsenoside-Ra1, ginsenoside-Ra2, ginsenoside-Ra3, ginsenoside-Rb1, ginsenoside-Rb2, ginsenoside -Rb3, Ginsenoside-Rc, Ginsenoside-Rd, Ginsenoside-Re, Ginsenoside-Rf, Ginsenoside-Rf2, Ginsenoside-Rg1, Ginsenoside-Rg2, Ginsenoside-Rg3 , Ginsenoside-Rg5, Ginsenoside-Rg6, Ginsenoside-Rh1, Ginsenoside-Rh2, Ginsenoside-Rh4, Notozinenoside-R1, Notozinenoside-R4, Ginsenoside-Rs1 , Ginsenoside-Rs2, ginsenoside-Rs3, ginsenoside-Rs4, 20 (S) -ginsenoside-Rg3, 20 (R) -ginsenoside-Rg2, 20 (R) -ginsenoside- Rh1, ginsenoside-F4, quinquenioside-R1 or 20-glucose-ginsenoside-Rf, preferably ginsenoside-Rb1, ginsenoside-Rb2 and ginsenoside-Rc Work .

In addition, the composition for co-administration of the present invention is not limited thereto, and piperine and ginseng saponin may be present in a 1: 0.1 to 20 weight ratio, preferably 1:10 to 15 weight ratio.

Saponin composition of the present invention for promoting absorption in the body can be prepared in a pharmaceutical or food composition, if necessary, can be prepared in a composition containing both a saponin component and pipelin.

In the case of the pharmaceutical composition, it may contain only saponin and piperin as active ingredients, or may further contain one or more pharmaceutically acceptable carriers, excipients or diluents.

The pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, it may include a variety of drug delivery materials used for oral administration to the peptide formulation. In addition, carriers for parenteral administration may include water, suitable oils, saline, aqueous glucose and glycols, and the like, and may further include stabilizers and preservatives. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. The pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent and the like in addition to the above components. Other pharmaceutically acceptable carriers can be found in Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, Pa., 1995).

The pharmaceutical composition may be formulated into oral or parenteral formulations according to the route of administration.

In the case of preparations for oral administration, the compositions of the present invention may be formulated using methods known in the art as powders, granules, tablets, pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions and the like. Can be. For example, oral formulations can be obtained by tablets or dragees by combining the active ingredients with solid excipients, milling them, adding suitable auxiliaries and then processing them into granule mixtures. Examples of suitable excipients include, but are not limited to, sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches including corn starch, wheat starch, rice starch and potato starch, Cellulose such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose and the like, fillers such as gelatin, polyvinylpyrrolidone and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may optionally be added as a disintegrant. Furthermore, the pharmaceutical composition of the present invention may further include an anticoagulant, a lubricant, a humectant, a perfume, an emulsifier, a preservative, and the like.

In the case of a preparation for parenteral administration, it can be formulated by a method known in the art in the form of injection, cream, lotion, external ointment, oil, moisturizer, gel, aerosol and nasal aspirate. These formulations are described in Remington's Pharmaceutical Science, 15th edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, a commonly known formulary for all pharmaceutical chemistries.

In addition, when prepared with a food composition, it may include all forms, such as functional food (nutritional supplement), health food (health food) and food additives (food additives).

Food compositions of this type can be prepared in various forms according to conventional methods known in the art. For example, but not limited to, health foods, saponin physiological absorption promoting composition comprising piperine as an active ingredient in the form of tea, juice and drinks to be liquefied, granulated, encapsulated and powdered for drinking It can be consumed by becoming angry. In addition, functional foods include, but are not limited to, beverages (including alcoholic beverages), fruits and processed foods (e.g. canned fruit, canned food, jams, marmalade, etc.), fish, meat and processed foods (e.g. ham) , Sausage cornbeans, etc., breads and noodles (e.g. udon, soba noodles, ramen noodles, spaghetti, macaroni, etc.), fruit juices, various drinks, cookies, candy, dairy products (e.g. butter, cheese, etc.), edible vegetable oils, margarine , Vegetable protein, retort food, frozen food, various seasonings (eg, miso, soy sauce, sauce, etc.) can be prepared by adding a golden extract and Gilyeong extract. In addition, in order to use the composition for promoting absorption in the body saponin containing piperine as an active ingredient in the form of food additives can be prepared in powder or concentrate form.

In addition, the compositions of the present invention may be formulated such that, but not limited to, piperine and ginseng saponin are present in one container in the form of a mixture, and may be formulated to be present in separate containers for simultaneous or sequential administration. Can be.

The method of administering the composition of the present invention is not limited to that method and can be administered by any method. For example, it can be administered orally or parenterally. Parenteral methods of administration include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal administration Can be. The composition of the present invention is not particularly limited to its formulation, route of administration, and method of administration as long as the effect is exhibited.

In addition, the present invention relates to an antioxidant composition comprising piperine and saponin as active ingredients.

In one embodiment of the present invention, when combined administration of pipelin and ginseng saponin, it has been shown that it can enhance the antioxidant effect of saponins. When the saponin alone was administered, the amount of polyphenol and SOD content in the blood were measured, and the amount and the SOD content of polyphenol in the blood were measured when co-administered with piperine. It was confirmed that the amount of and the SOD content increased significantly. Therefore, it was found that pipelin helped the absorption of saponin in the body, thereby maximizing the antioxidant effect of saponin.

As discussed above, the present invention provides a composition for promoting absorption in the body of saponin containing piperine as an active ingredient, and ginseng saponin for absorption in combination with piperine and ginseng saponin, including piperine and ginseng saponin as active ingredients. It relates to a composition for. When the black pepper-derived piperine of the present invention is administered in combination with ginseng saponin, it promotes the conversion of ginseng saponin to compound K, which is an absorbed form of the body, and has an effect of remarkably enhancing the amount of absorption in the body as compared with a single administration of saponin. .

Figure 1 shows the results of comparing the content of ginsenoside Rb1 in the blood when a single administration of saponin (Pulmuone red ginseng tablets) and when co-administered with piperine.
Figure 2 shows the results of comparing the content of ginsenosides Rb2 and Rc in the blood when a single administration of saponin (Pulmuone red ginseng tablets) and when co-administered with piperine.
Figure 3 shows the results of comparing the content of the compound K in the blood when a single administration of saponin (Pulmuone red ginseng tablets) and when co-administered with piperine.
Figure 4 shows the comparison of the amount of polyphenols in the blood when the pipelin and saponin in combination and saponin alone administration.
5 is a comparison of SOD content in blood when pipelin and saponin are administered in combination and when saponin is administered alone.

Hereinafter, the present invention will be described in detail by way of examples.

However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

&Lt; Example 1 >

Effect of Pipeline on Ginseng Saponin Absorption

In the present invention, piperine was supplied by SABIN, Japan (trade name; Bioferrin), and red ginseng concentrate was used Pulmuone red ginseng tablet with a saponin content of 3 mg / g.

<1-1> Ginseng Saponin Enhancement in the Body

The rats for this experiment were 7-week-old male wista rats weighing about 200 g and were supplied from Dooyeol Biotech (Korea). The rats were acclimated for one week in the animal cage and randomly divided into five groups per group, the normal control group, the red ginseng alone group, and the red ginseng and pipelin combination group. The animal breeding room was maintained at a temperature of 20 ± 3 ° C. and a humidity of 55%, and the brightness was illuminated every 12 hours. During the breeding period, food and water were freely consumed.

Wista rats were acclimated for one week and then orally administered to each experimental group. The sample dose was 3 g of red ginseng concentrate per wista rat for the red ginseng alone treatment group, and 3 g of red ginseng concentrate and 80 mg / g of piperine per wista rat for oral administration. Did not do it.

After oral administration, blood was collected after 1hr, 2hr, and 3hr in the eye, and after 5hr, the animal was sacrificed and blood was collected from the heart by centrifugation for 15 minutes at 4000rpm for 15 minutes.The separated serum was stored in -70 ℃ deep freezer. Used as a sample. 50 μl of serum was added to 200 μl of MeOH, and the resultant was allowed to stand for 20 minutes in a 60 ° C. water bath. LC MS / MS models were analyzed by Finnigan TSQ Quantum Ultra EMR. Analysis conditions were carried out under the conditions shown in Tables 1 and 2. Ginsenoside standards are prepared using 9 standard materials (compound K, Rh2, Rb1, Rb2, Rc, Rd, Re, Rg1, Rg3) purchased from Vitigin, and the content is calculated from each peak area ratio. Calculated.

Time (min) Flow (ml / min) % A % B Initial 1.6 ml / min 80 20 10 1.6 ml / min 80 20 40 1.6 ml / min 78 22 55 1.6 ml / min 50 50 70 1.6 ml / min 35 65 72 1.6 ml / min 10 90 82 1.6 ml / min 0 100 84 1.6 ml / min 80 20 90 1.6 ml / min 80 20

LC MS / MS Analysis Conditions Ion source ESI Negative polarity - Spray voltage 3500 Sheath gas pressure 35 Aux gas pressure 15 Capillary temperature 280 ℃

<1-3> Ginsenoside Rb1, Rb2, Rc Contents in Serum after Piperine Administration

After ginsenoside standard separation, the contents of ginsenosides Rb1, Rb2, and Rc were analyzed by LC MS / MS and shown in FIGS. 1 and 2.

As a result, as shown in Figure 1, in the case of ginsenoside Rb1, the contents of the red ginseng and the piperine combined group after 1 hour, 2 hours, 3 hours, 5 hours orally 14.791ng / ml, 10.029ng / ml, respectively , 7.501ng / ml, 6.209ng / ml showed the highest content after 1 hour of oral administration, and it was confirmed that the Rb1 content was lowered after 1 hour. In the case of the red ginseng alone group, the content after 1 hour, 2 hours, 3 hours, and 5 hours after administration was 2.65ng / ml, 3.562ng / ml, 8.528ng / ml, and 5.664ng / ml. The Rb1 content was lower than that of the red ginseng and pipelin combination group. This resulted in the highest absorption of red ginseng and piperine compared to the red ginseng alone group, which showed the highest absorption after 3 hours of oral administration, and the absorption of metabolism and content of ginsenoside Rb1 was enhanced by piperine promoting metabolism after 1 hour of oral administration. It was confirmed to increase.

In addition, ginsenosides Rb2, Rc was analyzed by LC MS / MS of the red ginseng alone group and the red ginseng and piperin combination group, and the results were shown as chromatograms.

As a result, as shown in Figure 2, the retention time of Rb2 is 9.68, the retention time of Rc is 9.44, and the Rb2 content of the red ginseng and piperine combination group is 17.952 after 1 hour, 2 hours, 3 hours, and 5 hours of oral administration. ng / ml, 8.929 ng / ml, 6.68 ng / ml, 5.019 ng / ml and the Rc content was 15.2812 ng / ml, 4.251 ng / ml, 3.368 ng / ml, 3.132 ng / ml. Rb2 content of red ginseng mononuclear group was ND, 3.19 ng / ml, 9.465 ng / ml, 4.525 ng / ml after 1 hour, 2 hours, 3 hours and 5 hours of oral administration, and Rc content was 1.195 ng / ml, 1.829 ng / ml, 6.681 ng / ml, 3.038 ng / ml. Like Rb1, Rb2 and Rc also showed the highest absorption of red ginseng and piperin combined group after 1 hour after oral administration due to metabolic promoting action of piperin, and showed higher content than red ginseng alone group.

<1-4> Changes in Compound K Content in Serum During Piperine Administration

Compound K content of the red ginseng alone group and the red ginseng and pipelin combination group was analyzed by LC MS / MS.

The retention time at which the compound K peak was shown was 13.93 minutes, and FIG. 3A shows the chromatogram of the red ginseng and piperine complex group. After 1 hour after oral administration, red ginseng and piperin uptake did not appear, and after 2 hours, the highest absorption was 16.6ng / ml, and after 3 hours, absorption was decreased by 13.75ng / ml compared to 2 hours after oral administration. After 5 hours of oral administration, the lowest value was 0.5ng / ml.

As a result, compound K showed the highest absorption after 2 hours of oral administration, and ginsenosides Rb1, Rb2, and Rc, which were difficult to absorb in the body, showed the highest absorption after 1 hour of oral administration, and fell sharply after 2 hours of oral administration. It was.

Through the above results, it was confirmed that the compound is converted into Compound K after oral administration 2 hours by the metabolic promoting action of piperine and is absorbed in the body. Compound K of the red ginseng alone group did not show chromatogram peaks from 1 hour to 5 hours after oral administration, resulting in a chromatogram peak in the group of red ginseng and piperin added with piperine alone in the same amount of red ginseng. It was found that piperine promotes the absorption of Compound K, a saponin metabolite that is absorbed into the body.

<Example 2>

Pharmacological Activity Enhancing Effect of Ginseng Saponin

In order to confirm that piperine enhances the pharmacological activity of ginseng saponin, the polyphenol content and SOD-like activity in blood of the ginseng saponin-administered group and the co-administration group of piperine and ginseng saponin were measured.

As a result, as shown in Figure 4, the polyphenol content according to time after oral administration of the red ginseng alone administration group is 5.4mg / 100g, 41.7mg / 100g, 26.1mg / 100g, 16mg after 0hr, 1hr, 2hr, 3hr, 5hr / 100g, 10.4mg / 100g, and the combination of red ginseng and piperin group was 5.4mg / 100g, 49.6mg / 100g, 32.2mg / 100g, 25.8mg / 100g, 19.1mg / 100g after 1 hour of oral administration. The red ginseng and pipelin combination group showed higher contents than the red ginseng alone group.

In addition, as shown in Figure 5, SOD-like activity measurement results in the red ginseng group was 0.8%, 21.9%, 32.7%, 11.1%, 4.8% after oral administration 0hr, 1hr, 2hr, 3hr, 5hr, 0.8%, 27.9%, 44.5%, 16.8%, 4.7% confirmed that the red ginseng and piperine combined group showed higher content than the red ginseng single-administered group, and showed the highest content after 2 hours of oral administration.

The results suggest that piperine promotes the conversion of ginsenosides Rb1, Rb2, and Rc into compound K, a major metabolite of saponin, which is difficult to absorb in the body by metabolic promoting action, thereby promoting the absorption of saponin in the body. there was. In addition, as a result of measuring the polyphenol and SOD-like activity in serum, the combination group of red ginseng and pipelin showed higher contents than the group of red ginseng alone. This confirmed that piperine has an effect of promoting the absorption of saponin in the body.

The present invention relates to a composition for promoting the absorption of saponin in the body containing piperine as an active ingredient and a composition for promoting the absorption of ginseng saponin for the combined administration of piperine and ginseng saponin containing piperine and ginseng saponin as an active ingredient, More specifically, the present invention relates to a composition capable of improving the absorption rate of saponin by promoting metabolism of saponin introduced into the body by the black pepper-derived piperine and enhancing the conversion into compound K, which is an absorption form in the body. The composition can further maximize the pharmacological effect of ginseng saponin in the human body.

Claims (6)

Ginsenoside-Ra1, Ginsenoside-Ra2, Ginsenoside-Ra3, Ginsenoside-Rb1, Ginsenoside-Rb2, Ginsenoside-Rb3, Gins in the gut Ginsenoside-Rc, Ginsenoside-Rd, Ginsenoside-Rh2, Notoginsenoside-R4, Ginsenoside-Rs1, Ginsenoside-Rs2, Ginsenoside-Rs3, Ginsenoside-Rs4, 20 ( S)-ginsenoside-Rg3 and quinquenoside (quinquenoside)-a composition for promoting absorption in ginseng saponin body to promote the conversion of one or more ginseng saponins to the compound K (Compound K) selected from the group consisting of.
Ginsenoside-Ra1, Ginsenoside-Ra2, Ginsenoside-Ra3, Ginsenoside-Rb1, Ginsenoside-Rb2, Ginsenoside- including piperine and ginseng saponin as active ingredients Rb3, Ginsenoside-Rc, Ginsenoside-Rd, Ginsenoside-Rh2, Notoginsenoside-R4, Ginsenoside-Rs1, Ginsenoside-Rs2, Ginsenoside-Rs3, Ginsenoside-Rs4 Administration of piperine and ginseng saponin to promote the conversion of at least one ginseng saponin to Compound K, selected from the group consisting of 20 (S) -ginsenoside-Rg3 and quinquenoside-R1 Ginseng saponin composition for promoting absorption in the body.
According to claim 2, wherein the composition is a composition, characterized in that the piperine and ginseng saponin is present in a weight ratio of 1: 0.1 to 20.
According to claim 2, wherein the composition is characterized in that the piperine and ginseng saponin is present in a weight ratio of 1:10 to 15.
The composition of claim 2, wherein the composition is formulated such that the piperine and ginseng saponins are present in one container in the form of a mixture.
The composition of claim 2, wherein the composition is formulated such that piperine and ginseng saponin are present in separate containers and administered simultaneously or sequentially.

Images